LAURUSLABS.NS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 12:00):

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally...

Stats
Dagens volum	2.18M
Gjennomsnittsvolum	2.19M
Markedsverdi	239.17B
EPS	INR0 ( 2024-04-24 )
Neste inntjeningsdato	( INR0 ) 2024-07-25
Last Dividend	INR1.200 ( 2023-05-10 )
Next Dividend	INR0 ( N/A )
P/E	149.41
ATR14	INR0.362 (0.08%)

Volum Korrelasjon

Lang: 0.57 (weak)

Kort: -0.75 (moderate negative)

Signal:(64.619) Neutral

Laurus Labs Limited Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Laurus Labs Limited Korrelasjon - Valuta/Råvare

0.26
( neutral )

0.47
( neutral )

-0.08
( neutral )

0.51
( weak )

-0.64
( weak negative )

-0.46
( neutral )

Laurus Labs Limited Økonomi

Annual	2023
Omsetning:	INR50.41B
Bruttogevinst:	INR15.84B (31.42 %)
EPS:	INR2.98

FY	2023
Omsetning:	INR50.41B
Bruttogevinst:	INR15.84B (31.42 %)
EPS:	INR2.98

FY	2022
Omsetning:	INR60.41B
Bruttogevinst:	INR32.66B (54.07 %)
EPS:	INR14.69

FY	2022
Omsetning:	INR48.89B
Bruttogevinst:	INR26.40B (54.01 %)
EPS:	INR15.42

Financial Reports:

No articles found.

Laurus Labs Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0.800 (N/A)	INR0 (N/A)	INR1.200 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Laurus Labs Limited Dividend Information - Dividend Knight

Dividend Sustainability Score: 8.01 - good (80.15%) | Divividend Growth Potential Score: 5.86 - Stable (17.17%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.300	2017-07-06
Last Dividend	INR1.200	2023-05-10
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	12	--
Total Paid Out	INR7.40	--
Avg. Dividend % Per Year	0.35%	--
Score	3.34	--
Div. Sustainability Score	8.01
Div.Growth Potential Score	5.86
Div. Directional Score	6.94	--

Next Divdend (Est)
(2024-05-13)

INR1.329 Estimate 3.60 %

Dividend Stability

0.29 Very Poor

Dividend Score

3.34

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2017	INR0	0.00%
2018	INR0.300	0.30%
2019	INR0.300	0.39%
2020	INR1.300	1.77%
2021	INR2.00	0.57%
2022	INR2.00	0.38%
2023	INR1.200	0.32%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SARDAEN.NS	Dividend Junior	2023-09-07	Annually	15	0.65%
MAGADSUGAR.NS	Dividend Junior	2023-07-13	Annually	7	1.78%
GMDCLTD.NS	Dividend Knight	2023-09-22	Annually	23	3.41%
ASTRAMICRO.NS	Dividend Junior	2023-08-23	Annually	20	0.49%
TITAN.NS	Dividend Junior	2023-07-13	Annually	20	0.35%
PETRONET.NS	Dividend Knight	2023-08-18	Semi-Annually	18	2.36%
JASH.NS	Dividend Junior	2023-09-22	Annually	7	0.57%
DBOL.NS	Dividend Junior	2023-06-23	Insufficient data to determine frequency	2	0.56%
SILINV.NS	Dividend Junior	2023-08-18	Annually	23	0.63%
MBAPL.NS	Dividend Junior	2023-09-18	Annually	8	0.44%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0318	1.500	9.36	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0191	1.200	9.36	10.00	[0 - 0.3]
returnOnEquityTTM	0.0396	1.500	-0.672	-1.007	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.232	0.800	8.84	7.07	[1 - 3]
quickRatioTTM	0.584	0.800	-1.272	-1.017	[0.8 - 2.5]
cashRatioTTM	0.0455	1.500	-0.858	-1.287	[0.2 - 2]
debtRatioTTM	0.300	-1.500	5.00	-7.50	[0 - 0.6]
interestCoverageTTM	2.19	1.000	-0.300	-0.300	[3 - 30]
operatingCashFlowPerShareTTM	10.62	2.00	6.46	10.00	[0 - 30]
freeCashFlowPerShareTTM	10.62	2.00	4.69	9.38	[0 - 20]
debtEquityRatioTTM	0.612	-1.500	7.55	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.465	1.000	5.58	5.58	[0.2 - 0.8]
operatingProfitMarginTTM	0.0795	1.000	-0.410	-0.410	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.227	1.000	9.85	9.85	[0.2 - 2]
assetTurnoverTTM	0.601	0.800	9.33	7.46	[0.5 - 2]
Total Score				8.01

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	146.33	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0396	2.50	-0.432	-1.007	[0.1 - 1.5]
freeCashFlowPerShareTTM	10.62	2.00	6.46	9.38	[0 - 30]
dividendYielPercentageTTM	0.459	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.62	2.00	6.46	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.517	1.500	9.89	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.114	1.000	9.66	0	[0.1 - 0.5]
Total Score				5.86

Laurus Labs Limited

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.